The ESMO Congress is one of the leading European cancer congresses, organized annually by the European Society for Medical Oncology (ESMO). It provides a multidisciplinary platform to share the latest advances in cancer treatment and research with an international audience of experts.
This year, the impressive ESMO 2024 congress will take place in Barcelona, where we will be on site with the following presentations.
3 GBG posters will be presented on Monday, September 16, 2024, during the Poster Lunch 12:00 - 13:00 and will be made available for download on this page afterwards:
Penelope-B OS (P241):S. Loibl
“Overall survival and updated invasive disease free survival results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after NACT”
Inflammatory BC (P249):L. Michel
“Neoadjuvant chemotherapy in inflammatory breast cancer: A meta-analysis of 10 trials of the German Breast Group (GBG)”
GeparOla RAD51 (P266):G. Villacampa
“Association of RAD51 and efficacy outcomes in patients with HER2-negative breast cancer (BC) and homologous recombination deficiency (HRD): post-hoc analysis of the GeparOla trial”
External presentation:
ASCENT (P392):A. Brufsky
“Quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST) analysis to assess benefit-risk of sacituzumab govitecan (SG) in previously treated patients (pts) with metastatic triple-negative breast cancer (mTNBC)”
Oral presentation:
In addition, our GBG Chair will give a presentation on treatment options for young women entitled “How to treat very young patients with ER+, node positive BC”.
Download links
Penelope OS
[Translate to English:]
